Technology

Recombinant Vaccine Against Porcine Circovirus Type 2

APTAAgropecuario

Recombinant porcine circovirus type 2 vaccine (PCV2), based on a chimeric variant of the CAP protein, which is boosted with an immunomodulator.

Advantages

This vaccine has shown to be able to control subclinical infection, taking the viral load to indetectable by qPCR assay. Current commercial anti-PCV2 vaccines are based on immunogens, which generate neutralizing antibodies that control the clinical course of the disease, but have not been able to control subclinical infection, maintaining viral infection in the swine population and the threat of resurgence. of clinical disease.

Agenda una reunión con nosotros

Completa el formulario O llama al + 56 9 4065 5017

Suscríbete a nuestro briefing

Al enviar tus datos, aceptas nuestros términos y condiciones para recibir nuestros contenido.